financetom
Business
financetom
/
Business
/
TopBuild Q1 Sales Dip, EPS Tops Estimates, Seal-Rite Deal Boosts Long-Term Outlook, Guidance Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TopBuild Q1 Sales Dip, EPS Tops Estimates, Seal-Rite Deal Boosts Long-Term Outlook, Guidance Reaffirmed
May 26, 2025 2:06 AM

TopBuild Corp. ( BLD ) shares were trading higher premarket on Tuesday after the company reported first-quarter 2025 sales of $1.23 billion, which was in line with the consensus.

Sales declined 3.6% YoY, mainly due to a 6.7% drop in the Installation segment, driven by a slow start in new residential construction.

Adjusted gross margin contracted to 29.6% from 30.3% a year ago, while adjusted EBITDA Margin declined to 19% from 19.8% in the prior-year quarter.

Adjusted EPS of $4.63, down from $4.81 a year ago, exceeded the consensus of $4.42.

BLD's net cash provided by operating activities for the quarter stood at $152.58 million, down from $178.78 million a year ago. As of March 31, cash and cash equivalents stood at $308.811 million.

TopBuild ( BLD ) bought back 693,881 shares for $215.6 million, leaving $972.4 million available for future repurchases at the quarter's end.

During the quarter, TopBuild ( BLD ) announced its acquisition of Seal-Rite Insulation, an Omaha-based fiberglass and spray foam installer that has served residential and commercial markets for over 25 years. Seal-Rite generates around $15 million in annual revenue, and the deal was finalized in April.

The company acknowledged near-term economic uncertainty but expressed confidence in its ability to adapt and outperform. It is adjusting its cost structure to match current demand, continuing targeted investments, and pursuing operational improvements. The company remains optimistic about mid- and long-term prospects, citing strong U.S. housing demand and positive trends in commercial and industrial markets.          

2025 Outlook, reaffirmed: TopBuild ( BLD ) projects FY25 sales of $5.05 billion-$5.35 billion, vs. previous estimate of $5.17 billion, with adjusted EBITDA expected between $925 million and $1.075 billion

Price Action: At the last check on Tuesday, BLD shares were trading higher, 1.67%, at $296.87.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rbc Bearings Insider Sold Shares Worth $837,202, According to a Recent SEC Filing
Rbc Bearings Insider Sold Shares Worth $837,202, According to a Recent SEC Filing
Sep 21, 2024
04:08 PM EDT, 09/20/2024 (MT Newswires) -- Edward Stewart, Director, on September 20, 2024, sold 2,800 shares in Rbc Bearings ( RBC ) for $837,202. Following the Form 4 filing with the SEC, Stewart has control over a total of 20,461 shares of the company, with 20,461 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1324948/000159396824001214/xslF345X05/primary_01.xml Price: 295.45, Change: +0.11, Percent Change: +0.04...
Longevity Biomedical to Go Public in SPAC deal with FutureTech II Acquisition
Longevity Biomedical to Go Public in SPAC deal with FutureTech II Acquisition
Sep 21, 2024
03:56 PM EDT, 09/20/2024 (MT Newswires) -- Blank-check firm FutureTech II Acquisition ( FTII ) agreed to a merger agreement earlier this week and take Longevity Biomedical public, the companies said Friday. The combined company will operate as Longevity Biomedical and is expected to list on Nasdaq under the LBIO ticker, the companies said. The new company will have approximately...
Rev Group Insider Sold Shares Worth $356,250, According to a Recent SEC Filing
Rev Group Insider Sold Shares Worth $356,250, According to a Recent SEC Filing
Sep 21, 2024
04:09 PM EDT, 09/20/2024 (MT Newswires) -- Charles Dutil, Director, on September 18, 2024, sold 12,500 shares in Rev Group ( REVG ) for $356,250. Following the Form 4 filing with the SEC, Dutil has control over a total of 41,628 shares of the company, with 41,628 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1687221/000095010324013803/xslF345X05/dp218237_4.xml Price: 27.61, Change: -0.01, Percent Change: -0.04...
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi wins US approval for drug combination to treat multiple myeloma
Sep 21, 2024
Sept 20 - Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved